Filing Details

Accession Number:
0001209191-23-004871
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-01-25 17:50:27
Reporting Period:
2023-01-23
Accepted Time:
2023-01-25 17:50:27
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
25743 Therapeuticsmd Inc. TXMD Pharmaceutical Preparations (2834) 870233535
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1627810 C Michael Donegan 951 Yamato Road
Suite 220
Boca Raton FL 33431
Prin. Fin. And Acctg. Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-01-23 380 $0.00 4,934 No 4 M Direct
Common Stock Acquisiton 2023-01-23 1,066 $0.00 6,000 No 4 M Direct
Common Stock Acquisiton 2023-01-23 519 $0.00 6,519 No 4 M Direct
Common Stock Acquisiton 2023-01-23 2,400 $0.00 8,919 No 4 M Direct
Common Stock Disposition 2023-01-23 1,302 $5.34 7,617 No 4 S Direct
Common Stock Disposition 2023-01-24 7 $5.31 7,610 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2023-01-23 380 $0.00 380 $0.00
Common Stock Restricted Stock Units Disposition 2023-01-23 1,066 $0.00 1,066 $0.00
Common Stock Restricted Stock Units Disposition 2023-01-23 519 $0.00 519 $0.00
Common Stock Restricted Stock Units Disposition 2023-01-23 2,400 $0.00 2,400 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 M Direct
0 No 4 M Direct
0 No 4 M Direct
0 No 4 M Direct
Footnotes
  1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On January 23, 2023, the reporting person received 4,365 shares of issuer common stock in settlement of restricted stock units (RSUs).
  2. The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices of ranging from $5.32 through $5.37, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth.
  4. The RSUs were to vest in three equal installments annually beginning March 30, 2021 and becoming fully vested on March 30, 2023. Vesting was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause".
  5. The RSUs were to vest in three equal installments annually beginning July 1, 2022 and becoming fully vested on July 1, 2024. Vesting was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause".
  6. Subject to the reporting person's continuous service, the RSUs were to vest in three equal installments annually, beginning September 29, 2022 and becoming fully vested on September 29, 2024. Vesting was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause".
  7. The RSUs were to vest in three equal installments annually beginning March 23, 2023 and becoming fully vested on March 23, 2025. Vesting was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause".